Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2252-2262

  Johnston, Andrew ^a   Fritz, Yi ^b   Dawes, Sean M ^b   Diaconu, Doina ^b   Al Attar, Paul M ^a   Guzman, Andrew M ^a   Chen, Cynthia S ^a   Fu, Wen ^b   Gudjonsson, Johann E ^a   McCormick, Thomas S ^b,c   Ward, Nicole L ^b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CYTOKINE; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 19; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1F5; INTERLEUKIN 1F9; INTERLEUKIN 23P19; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEPTIDASE INHIBITOR 3; PSORIASIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; EPIDERMIS HYPERPLASIA; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; LEUKOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PSORIASIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-17; KERATINOCYTES; MICE; MICE, TRANSGENIC; MIDDLE AGED; PRIMARY CELL CULTURE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874256199     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201505     Document Type: Article

References (36)

1. Iwakura, Y., H. Ishigame, S. Saijo, and S. Nakae. 2011. Functional specialization of interleukin-17 family members. Immunity 34: 149-162.
2. Li, H., J. Chen, A. Huang, J. Stinson, S. Heldens, J. Foster, P. Dowd, A. L. Gurney, andW. I. Wood. 2000. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc. Natl. Acad. Sci. USA 97: 773-778.
3. Bordon, Y. 2011. Cytokines: IL-17C joins the family firm. Nat. Rev. Immunol. 11: 805.
4. Johansen, C., J. L. Riis, A. Gedebjerg, K. Kragballe, and L. Iversen. 2011. Tumor necrosis factor a-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor kB. J. Biol. Chem. 286: 25487-25494.
5. Ramirez-Carrozzi, V., A. Sambandam, E. Luis, Z. Lin, S. Jeet, J. Lesch J. Hackney, J. Kim, M. Zhou, J. Lai, et al. 2011. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12: 1159-1166.
6. Song, X., S. Zhu, P. Shi, Y. Liu, Y. Shi, S. D. Levin, and Y. Qian. 2011. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12: 1151-1158.
7. Im, E., J. Jung, and S. H. Rhee. 2012. Toll-Like Receptor 5 Engagement Induces Interleukin-17C Expression in Intestinal Epithelial Cells. J. Interferon Cytokine Res. 32: 583-591.
8. Reynolds, J. M., G. J. Martinez, K. C. Nallaparaju, S. H. Chang, Y. H. Wang, and C. Dong. 2012. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J. Immunol. 189: 4226-4230.
9. Chang, S. H., J. M. Reynolds, B. P. Pappu, G. Chen, G. J. Martinez, and C. Dong. 2011. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35: 611-621.
10. Johansen, C., P. A. Usher, R. B. Kjellerup, D. Lundsgaard, L. Iversen, and K. Kragballe. 2009. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 160: 319-324.
11. Johansen, C., H. Vinter, L. Soegaard-Madsen, L. R. Olsen, T. Steiniche, L. Iversen, and K. Kragballe. 2010. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFa therapy. Br. J. Dermatol. 163: 1194-1204.
12. El Malki, K., S. H. Karbach, J. Huppert, M. Zayoud, S. Reißig, R. Schüler, A. Nikolaev, K. Karram, T. Münzel, C. R. Kuhlmann, et al. 2013. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J. Invest. Dermatol. 133: 441-451.
13. Chiricozzi, A., E. Guttman-Yassky, M. Suárez-Fariñas, K. E. Nograles, S. Tian, I. Cardinale, S. Chimenti, and J. G. Krueger. 2011. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131: 677-687.
14. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
15. Papp, K. A., C. Leonardi, A. Menter, J. P. Ortonne, J. G. Krueger, G. Kricorian, G. Aras, J. Li, C. B. Russell, E. H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-1189.
16. Elder, J. T., G. J. Fisher, Q. Y. Zhang, D. Eisen, A. Krust, P. Kastner, P. Chambon, and J. J. Voorhees. 1991. Retinoic acid receptor gene expression in human skin. J. Invest. Dermatol. 96: 425-433.
17. Johnston, A., J. E. Gudjonsson, A. Aphale, A. M. Guzman, S. W. Stoll, and J. T. Elder. 2011. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J. Invest. Dermatol. 131: 329-337.
18. Johnston, A., X. Xing, A. M. Guzman, M. Riblett, C. M. Loyd, N. L. Ward, C. Wohn, E. P. Prens, F. Wang, L. E. Maier, et al. 2011. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186: 2613-2622.
19. Ward, N. L., P. Van Slyke, and D. J. Dumont. 2004. Functional inhibition of secreted angiopoietin: a novel role for angiopoietin 1 in coronary vessel patterning. Biochem. Biophys. Res. Commun. 323: 937-946.
20. Bureau, W., P. Van Slyke, J. Jones, R. N. N. Han, N. L. Ward, D. J. Stewart, and D. J. Dumont. 2006. Chronic systemic delivery of angiopoietin-2 reveals a possible independent angiogenic effect. Am. J. Physiol. Heart Circ. Physiol. 291: H948-H956.
21. Logan, C., W. K. Khoo, D. Cado, and A. L. Joyner. 1993. Two enhancer regions in the mouse En-2 locus direct expression to the mid/hindbrain region and mandibular myoblasts. Development 117: 905-916.
22. Diamond, I., T. Owolabi, M. Marco, C. Lam, and A. Glick. 2000. Conditional gene expression in the epidermis of transgenic mice using the tetracyclineregulated transactivators tTA and rTA linked to the keratin 5 promoter. J. Invest. Dermatol. 115: 788-794.
23. Wolfram, J. A., D. Diaconu, D. A. Hatala, J. Rastegar, D. A. Knutsen, A. Lowther, D. Askew, A. C. Gilliam, T. S. McCormick, and N. L. Ward. 2009. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am. J. Pathol. 174: 1443-1458.
24. Yamaguchi, Y., K. Fujio, H. Shoda, A. Okamoto, N. H. Tsuno, K. Takahashi, and K. Yamamoto. 2007. IL-17B and IL-17C are associated with TNF-αlpha production and contribute to the exacerbation of inflammatory arthritis. J. Immunol. 179: 7128-7136.
25. Nickoloff, B. J. 2007. Cracking the cytokine code in psoriasis. Nat. Med. 13: 242-244.
26. Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
27. Mease, P. J., B. S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D. J. Burge. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390.
28. Gottlieb, A. B., R. T. Matheson, N. Lowe, G. G. Krueger, S. Kang, B. S. Goffe, A. A. Gaspari, M. Ling, G. D. Weinstein, A. Nayak, et al. 2003. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139: 1627-1632, discussion 1632.
29. Leonardi, C. L., J. L. Powers, R. T. Matheson, B. S. Goffe, R. Zitnik, A. Wang, and A. B. Gottlieb; Etanercept Psoriasis Study Group. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349: 2014-2022.
30. Ward, N. L., C. M. Loyd, J. A. Wolfram, D. Diaconu, C. M. Michaels, and T. S. McCormick. 2011. Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br. J. Dermatol. 164: 750-758.
31. Nograles, K. E., L. C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suárez- Fariñas, I. Cardinale, A. Khatcherian, J. Gonzalez, K. C. Pierson, T. R. White, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159: 1092-1102.
32. Gudjonsson, J. E., J. Ding, X. Li, R. P. Nair, T. Tejasvi, Z. S. Qin, D. Ghosh, A. Aphale, D. L. Gumucio, J. J. Voorhees, et al. 2009. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J. Invest. Dermatol. 129: 2795-2804.
33. Shebl, F. M., L. A. Pinto, A. García-Piñeres, R. Lempicki, M. Williams, C. Harro, and A. Hildesheim. 2010. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol. Biomarkers Prev. 19: 978-981.
34. Caproni, M., E. Antiga, L. Melani, W. Volpi, E. Del Bianco, and P. Fabbri. 2009. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J. Clin. Immunol. 29: 210-214.
35. Russell, C. B., K. Kerkof, J. Bigler, M. Timour, R. L. Diaz, A. Symons, H. Rand, J. G. Krueger, and D. A. Martin. 2012. IL-17 Receptor A subunit is a central hub for inflammatory signaling in human psoriasis. J. Invest. Dermatol. 132: S7.
36. Papp, K. A., C. Reid, P. Foley, R. Sinclair, D. H. Salinger, G. Williams, H. Dong, J. G. Krueger, C. B. Russell, and D. A. Martin. 2012. Anti-IL-17 receptor antibody AMG 827 leads to Rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J. Invest. Dermatol. 132: 2466-2469.